In October 2012, the facility in Tamil Nadu was inspected and was found to have been breaching quality regulations during drugs manufacturing, as reported by Reuters.
The regulator also raised issues relating to sanitization, sterilisation and contamination for finalised products.
Hospira has been involved in many regulatory problems relating to its manufacturing facilities for the past three years and was banned in February 2013 by the FDA from importing certain products, as reported by the news agency.